FLGTFulgent Genetics, Inc.
$20.87-7.8% 1Y
$20.87
$13.7952 weeks$30.85
The financials
Fulgent Genetics, Inc. by the numbers
Fulgent Genetics, Inc. (FLGT) reported revenue of $85M in Q2 2026 (quarter ended Jun 30, 2026), up 4.4% from the same quarter a year earlier. That came with a gross margin of 30% and net loss of $30M. For the full year FY2025, revenue was $323M (+14% year on year) and net income −$61M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $85M | $82M | +4.4% |
| Gross profit | $26M | $34M | −25% |
| Operating income | −$36M | −$20M | n/a |
| Net income | −$30M | −$19M | n/a |
| Diluted EPS | −$1.05 | −$0.62 | n/a |
Diagnostics & Research
Ranks #14 of 21 by RyuScore